Société Antibe Therapeutics Inc Toronto S.E.
Actions
ATE
CA0370251039
Recherche biotechnologique et médicale
Métier
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 01/12/15 |
Chief Tech/Sci/R&D Officer | - | - | |
Ana Stegic
CTO | Chief Tech/Sci/R&D Officer | - | - |
Scott Curtis
COO | Chief Operating Officer | - | 01/01/16 |
Joseph Stauffer
CTO | Chief Tech/Sci/R&D Officer | 58 | 06/05/20 |
Investor Relations Contact | - | - | |
David Vaughan
PRN | Corporate Officer/Principal | 74 | 01/11/12 |
Corporate Officer/Principal | - | - |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Director/Board Member | 50 | 24/11/20 | |
Amal Khouri
BRD | Director/Board Member | - | 19/03/18 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 53 009 362 | 48 481 043 ( 91,46 %) | 0 | 91,46 % |
Coordonnées société
Antibe Therapeutics, Inc.
15 Prince Arthur Avenue
M5R 1B2, Toronto
+416-922-3460
http://www.antibethera.comSecteur
Varia. 1 janv. | Capi. | |
---|---|---|
+9,42% | 114 Md | |
+11,84% | 104 Md | |
-14,15% | 22,41 Md | |
-1,05% | 22,28 Md | |
-5,29% | 19,07 Md | |
-38,29% | 18 Md | |
-4,16% | 17,89 Md | |
+7,99% | 14,28 Md | |
+36,24% | 12,55 Md |